[4-[5-[2-(3-fluorophenyl)ethyl]-1,3,4-oxadiazol-2-yl]-2-pyridinyl]-(3-phenylpropyl)carbamic acid
C25H23FN4O3 — CID 68663450
Data last refreshed: (MolForge compound catalog, from PubChem)
About [4-[5-[2-(3-fluorophenyl)ethyl]-1,3,4-oxadiazol-2-yl]-2-pyridinyl]-(3-phenylpropyl)carbamic acid
[4-[5-[2-(3-fluorophenyl)ethyl]-1,3,4-oxadiazol-2-yl]-2-pyridinyl]-(3-phenylpropyl)carbamic acid (PubChem CID 68663450) has the molecular formula C25H23FN4O3 and a molecular weight of 446.48 g/mol. Its IUPAC name is [4-[5-[2-(3-fluorophenyl)ethyl]-1,3,4-oxadiazol-2-yl]-2-pyridinyl]-(3-phenylpropyl)carbamic acid.
Molecular Properties
| Compound Name | [4-[5-[2-(3-fluorophenyl)ethyl]-1,3,4-oxadiazol-2-yl]-2-pyridinyl]-(3-phenylpropyl)carbamic acid |
|---|---|
| PubChem CID | 68663450 |
| Molecular Formula | C25H23FN4O3 |
| Molecular Weight | 446.48 g/mol |
| Exact Mass | 446.18 |
| IUPAC Name | [4-[5-[2-(3-fluorophenyl)ethyl]-1,3,4-oxadiazol-2-yl]-2-pyridinyl]-(3-phenylpropyl)carbamic acid |
| SMILES | O=C(O)N(CCCc1ccccc1)c1cc(-c2nnc(CCc3cccc(F)c3)o2)ccn1 |
| InChI | InChI=1S/C25H23FN4O3/c26-21-10-4-8-19(16-21)11-12-23-28-29-24(33-23)20-13-14-27-22(17-20)30(25(31)32)15-5-9-18-6-2-1-3-7-18/h1-4,6-8,10,13-14,16-17H,5,9,11-12,15H2,(H,31,32) |
| InChIKey | XMABJLWPJNAQQC-UHFFFAOYSA-N |
| XLogP | 5.17 |
| TPSA | 92.35 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 446.48 |
| LogP ≤ 5 | 5.17 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 68663450 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.